Abstract
Poly ADP-ribose polymerase (PARP) inhibitors have transformed the treatment landscape of high-grade ovarian cancer.[1][1] The presence of homologous recombination deficiencies and particularly alterations in the BRCA genes are well described biomarkers of response.[2][2] Until the American Society
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Paper Title
Journal
Date
